Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Several prominent UK-based insurers including Aviva, Axa, and WPA will not cover the costs of the newly launched weight-loss drug, Wegovy, under their private medical insurance policies.  Since insurers typically cover acute conditions, which are characterised as diseases, illnesses, or injuries that are likely to respond quickly to treatment, the so-called “miracle” obesity drug developed by Novo Nordisk (NYSE:NVO) does not qualify.

‘Miracle' weight-loss drug Wegovy will not be issued through major insurers

Novo Nordisk launched its Wegovy weight loss injection in the U.K. Monday, furthering the drug's rollout in Europe despite ongoing supply constraints.

Novo Nordisk's Wegovy weight loss drug launches in the UK

Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe and Japan, even as it struggles to keep up with demand.

Launches of Novo Nordisk's weight-loss drug Wegovy

Novo Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe even as it struggles to keep up with demand. The Danish drugmaker is working to convince European governments and insurers to reimburse the drug, seeking to position it as more than a lifestyle drug.

Factbox: Launches of Novo Nordisk's weight-loss drug Wegovy

Novo Nordisk has launched its wildly popular weight-loss drug Wegovy in nine countries since 2021 at prices ranging from $200 to almost $2,000 a month as Eli Lilly starts selling its rival drug in Europe and the United States.

Launches and prices of Novo Nordisk's weight-loss drug Wegovy

Novo Nordisk has launched its wildly popular weight-loss drug Wegovy in 10 countries since 2021 at prices ranging from $200 to almost $2,000 a month as Eli Lilly starts selling its rival drug in Europe and the United States.

Weight-loss drug Wegovy: How much does it cost and where is it sold?

In August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.

Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New Peak

Novo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.

Novo Nordisk launches weight-loss drug Wegovy in UK

The maker of diabetes and weight-loss drugs Ozempic and Wegovy beat out the French luxury retailer behind brands like Louis Vuitton and Dior.

Ozempic Drug Maker Briefly Becomes Europe's Most Valuable Company

LVMH, which has been Europe's most valuable company for two-and-a-half years, was briefly overtaken on Friday by Ozempic maker Novo Nordisk.

Ozempic maker briefly overtook LVMH as Europe's most valuable company

Novo Nordisk (NYSE:NVO) became Europe's largest company for a short time today as investors continued to pile into the Danish drugmaker following the recent trial of fat-busting drug Wegovy. Shares in Novo have jumped 17% since the trial showed that not only can Wegovy trim the waistline but cuts the risk of heart attack or stroke by a fifth.

Novo Nordisk briefly becomes Europe's No1 as investors binge on weight-loss stocks

Astellas Pharma Inc

Amgen

Bristol-Myers

Horizon Pharma

Johnson & Johnson

Eli Lilly

Merck

Novartis

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

Danish drugmaker Novo Nordisk briefly unseated LVMH as Europe's most valuable listed company in intraday trading on Friday, ending the French luxury group's 2-1/2 year-long reign at the top.

Drugmaker Novo Nordisk briefly overtakes LVMH as Europe's most valuable company

Wall Street analysts expect Ozempic to be selected for price negotiations in 2025 due to the amount of money Medicare Part D already spends on the drug.

Ozempic could be the next target of Medicare drug price negotiations – here's why

Novo Nordisk is a high-quality pharmaceutical company with a unique ownership structure, controlled by a charitable foundation. The company specializes in diabetes and obesity treatments, with a focus on insulin and GLP-1 analogues. Despite a temporary slowdown in recent years, Novo Nordisk is back on track for strong growth and has the potential for further diversification in the future.

Novo Nordisk: Super Focused Pharma Company For The Long Run

Novo Nordisk is making strides in the weight loss and diabetes care markets, with strong financial performance and a diverse product portfolio. The company faces competition from Eli Lilly's GLP-1 treatment, but the expected market growth leaves room for multiple winners. Novo Nordisk's stock price displays a solid bullish trend, with potential for continued gains, but investors should be aware of potential price corrections.

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Wegovy maker Novo Nordisk (NVO) agreed to buy Embark Biotech for €15 million ($16 million) in cash upfront, in a move that could boost Novo Nordisk's portfolio of weight loss treatments. In addition, Embark shareholders could receive up to €456 million ($500 million), depending on whether certain commercial milestones are reached.

Wegovy Maker Novo Nordisk Buys Embark Biotech to Boost Edge in Weight Loss Treatments

We're getting Case-Shiller home price numbers ahead of the opening bell this morning, but there's not enough time to dig into it. Give us till this afternoon to speak about these.

10 Drugs Selected for Medicare Price Reduction

Novo Nordisk has seen huge success with Ozempic, which treats type 2 diabetes. Now, it has followed up with a similar drug, Wegovy, for addressing obesity.

Does the Red-Hot Weight-Loss Market Make This Pharmaceutical Stock a Buy?

AbbVie

AstraZeneca

Pfizer

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

Wegovy may generate more than $4 billion in revenue this year for Novo Nordisk. A recent study showed the weight-loss drug can also help people bring down their risk of heart attack or stroke.

Why Wegovy's Sales Potential Could Be Massively Understated

Vertex Pharmaceuticals

Vertex, Eli Lilly, and Novo Nordisk are growing their sales rapidly. All three biotechs have solid portfolios and highly promising pipelines.

3 Top Growth Stocks I'd Buy Right Now Without Hesitation

It's seeing unprecedented demand for its weight-loss and diabetes medications. But the Danish drugmaker faces stiff competition, primarily from Eli Lilly.

Is It Time to Take Some Gains in Novo Nordisk Stock? Not So Fast.

Novo Nordisk (NVO) announces positive results from its label-expanding study of Wegovy to treat patients with heart failure and obesity.

Novo Nordisk (NVO) Posts Upbeat Data From Heart Failure Study

Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.

News for Novo Nordisk Stock (NVO)